Best radiological response to trans-arterial chemoembolization for hepatocellular carcinoma does not imply better outcomes

HPB

Volumn 15, Issue 3, 2013, Pages 196-202

  Henry, Jon C ^a   Malhotra, Lavina ^a   Khabiri, Hooman ^a   Guy, Gregory ^a   Michaels, Anthony ^a   Hanje, James ^a   Azevedo, Marcela ^a   Bloomston, Mark ^a   Schmidt, Carl R ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IODIXANOL; MITOMYCIN;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TRANSARTERIAL CHEMOEMBOLIZATION;

EID: 84873410456     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00529.x     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Naishadham D, Jemal A,. (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
3. Marsh JW, Geller DA, Finkelstein SD, Donaldson JB, Dvorchik I,. (2004) Role of liver transplantation for hepatobiliary malignant disorders. Lancet Oncol 5: 480-488.
4. Altekruse SF, McGlynn KA, Reichman ME,. (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491.
5. Capussotti L, Ferrero A, Vigano L, Polastri R, Tabone M,. (2009) Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. Eur J Surg Oncol 35: 11-15.
6. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L,. (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242: 158-171.
7. Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, et al,. (2010) Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis 42: 515-519.
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al,. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739.
9. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al,. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171.
10. Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al,. (2012) Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol 81: 1173-1178.
11. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al,. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224: 47-54.
12. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, et al,. (2008) Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 98: 1161-1165.
13. Hsin IF, Hsu CY, Huang HC, Huang YH, Lin HC, Lee RC, et al,. (2011) Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol 45: 556-562.
14. Wigmore SJ, Redhead DN, Thomson BN, Parks RW, Garden OJ,. (2004) Predicting survival in patients with liver cancer considered for transarterial chemoembolization. Eur J Surg Oncol 30: 41-45.
15. Shim JH, Kim KM, Lee YJ, Ko GY, Yoon HK, Sung KB, et al,. (2010) Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol 17: 869-877.
16. Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, et al,. (2011) Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther 34: 196-204.
17. Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, et al,. (2011) Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 80: 188-194.
18. Kim SJ, Choi MS, Kang JY, Choi DI, Park CK, Gwak GY, et al,. (2009) Prediction of complete necrosis of hepatocellular carcinoma treated with transarterial chemoembolization prior to liver transplantation. Gut Liver 3: 285-291.
19. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al,. (2005) Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92: 1862-1868.
20. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS,. (2010) Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB 12: 174-180.
21. Jin B, Wang D, Lewandowski RJ, Ryu RK, Sato KT, Larson AC, et al,. (2011) Quantitative 4D transcatheter intraarterial perfusion MRI for standardizing angiographic chemoembolization endpoints. AJR Am J Roentgenol 197: 1237-1243.